Texas Children’s Hospital Center for Vaccine Development (CVD)

Safety and immunogenicity of booster doses of an XBB.1.5
RBD subunit COVID-19 vaccine among individuals aged 5–80
years in India: a phase 3, single-blind, randomised controlled
trial

Safety and Immunogenicity of Booster Doses of an XBB.1.5Download

Recombinant Protein COVID-19 Vaccine Technology

Since 2011, the BCM-Texas Children’s CVD has been developing recombinant protein coronavirus vaccines for SARS and MERS, and in 2020 developed the first recombinant protein COVID-19 through microbial fermentation in yeast.  The technology has been transferred to 4 entities to date: India (Biological E, CORBEVAX), Indonesia (BioFarma, CORONAVAC), Bangladesh (Incepta) and Botswana (ImmunityBio). In India and Indonesia, more than 100 million doses of these vaccines have been administered. CORBEVAX has also been authorized as an adult heterologous booster.  To date there are 8 scientific publications about laboratory development of the BCM-Texas Children’s CVD recombinant protein COVID-19 vaccine (in addition to 5 others on SARS/MERS (not shown), and 3 on the clinical trials see below):

From concept to delivery: a yeast-expressed recombinant protein-based COVID-19 vaccine technology suitable for global access
SARS‑CoV-2 RBD219-N1C1: A yeast-expressed SARS-CoV-2 recombinant receptor-binding domain candidate vaccine stimulates virus neutralizing antibodies and T-cell immunity in mice
Receptor-binding domain recombinant protein on alum-CpG induces broad protection against SARS-CoV-2 variants of concern
Yeast-expressed recombinant SARS-CoV-2 receptor binding domain RBD203-N1 as a COVID-19 protein vaccine candidate
Process development and scale-up optimization of the SARS-CoV-2 receptor binding domain-based vaccine candidate, RBD219-N1C1
Whole Inactivated Virus and Protein-Based COVID-19 Vaccines
Genetic modification to design a stable yeast-expressed recombinant SARS-CoV-2 receptor binding domain as a COVID-19 vaccine candidate

The published results from the clinical trials performed by Biological E Ltd. can be found in the following peer-reviewed articles: 

Immunogenicity and safety of Biological E’s CORBEVAX™ vaccine compared to COVISHIELD™ (ChAdOx1 nCoV-19) vaccine studied in a phase III, single blind, multicenter, randomized clinical trial
Safety, tolerability and immunogenicity of Biological E’s CORBEVAX vaccine in children and adolescents: A prospective, randomised, double-blind, placebo controlled, phase-2/3 study
Immunogenicity and Safety of SARS-CoV-2 Protein
Subunit Recombinant Vaccine (IndoVac()) as a Booster
Dose against COVID-19 in Indonesian Adults
Immunogenicity and safety of SARS-CoV-2 recombinant
protein subunit vaccine (IndoVac) adjuvanted with alum
and CpG 1018 in Indonesian adults: A phase 3, randomized,
active-controlled, multicenter trial